Recent Updates
Recently added Catalysts
BFRI

Biofrontera Inc. to Present at the LD Micro Main Event XV Investor Conference

Key Takeaway: WOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that Erica Monaco, Chief Executive Officer, will be presenting and meeting with register
Price reaction · baseline $24.4 (2022-10-19 close) · hit after-hours · 2 other BFRI headline(s) in the window, move may be shared
day 0 close · peak
+1.6%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+65%
120-day peak, hindsight
Typical move
14.8%
average across 3 past catalysts
Cash runway
~8 mo
Medium dilution risk
Lead asset
BF-200 ALA 1%
Phase 2 · Actinic Keratosis

Full Press Release Details

WOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that Erica Monaco, Chief Executive Officer, will be presenting and meeting with registered investors at the LD Micro Main Event XV that will be held October 25-27, 2022 at the Luxe Sunset Boulevard Hotel in Southern California.
Event: LD Micro Main Event XV
Date: Wednesday, October 26, 2022
Presentation Time : 4:00 PM Pacific Time (7:00 PM Eastern Time)
Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA
Webcast: https://me22.sequireevents.com
A webcast of the presentation will be live and archived on the News & Events section of the company website. Institutional investors registered for the conference who would like to meet with Erica Monaco and Hermann Lübbert, Executive Chairman of Biofrontera Inc., please contact LD Micro directly or the BFRI investor relations team.
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.
Last updated: Oct 20, 2022